Figure 1 | Scientific Reports

Figure 1

From: MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway

Figure 1

Lowered expression of miR-29c in NSCLC tissues is associated with NSCLC survival and cisplatin resistance. (A,B) The expression of miR-29c in the cancer tissues was lower than in the adjacent normal tissues examined by using qRT-PCR (P < 0.001, paired t-test, two-tailed). MiR-29c expression was calculated by 2−ΔΔCT method and U6 snRNA was used as an endogenous control. C: lung cancer tissues; N: the matched normal lung tissues. (C) The relative level of miR-29c in the early pTNM stage (I + II) and advanced pTNM stage (III + IV) patients analyzed by qRT-PCR. (D) The Kaplan-Meier survival curve. The relation between the overall survival rate of cancer patients and the miR-29c level was analyzed. Studies were performed with 97 out of 130 patients with NSCLC undergoing chemotherapy after resection and the survival information of whom could be obtained. (E) The recurrence of NSCLC patients who underwent cisplatin chemotherapy. NSCLC in patients with low levels of miR-29c tended to recur post cisplatin chemotherapy.

Back to article page